Relcovaptan is a selective vasopressin V2 receptor antagonist within the antidiuretic hormone antagonist class, primarily indicated for the management of conditions such as euvolemic hyponatremia and the… Read more
Relcovaptan is a selective vasopressin V2 receptor antagonist within the antidiuretic hormone antagonist class, primarily indicated for the management of conditions such as euvolemic hyponatremia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). By blocking vasopressin activity in the renal collecting ducts, this therapeutic agent promotes free water excretion. To support the rigorous analytical demands of pharmaceutical development, this category provides high-quality reference standards, including Relcovaptan impurities, active metabolites, and stable isotope-labelled compounds. These materials are essential for accurate impurity profiling, the validation of analytical methods, and routine quality control of the drug substance. Laboratories rely on these well-characterized standards to ensure precise quantification and regulatory compliance during the synthesis and stability testing of the parent compound throughout the drug lifecycle.